Dbv Technologies SA (UK) ((GB:0QAJ)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dbv Technologies SA is conducting a Phase 3 clinical study titled ‘A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy.’ The primary objective is to evaluate the 6-month safety of the DBV712 250 mcg patch in young children with peanut allergies, aiming to provide a new treatment option for this vulnerable age group.
The intervention being tested is the DBV712 250 mcg epicutaneous patch, designed to deliver immunotherapy through the skin. This patch aims to desensitize children to peanuts, reducing allergic reactions.
This study follows a randomized, parallel assignment model with triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocation. The primary purpose is treatment-focused, assessing the safety of the intervention.
The study began on June 24, 2025, with primary completion expected after the 6-month treatment period. The last update was submitted on July 1, 2025. These dates are crucial for tracking progress and anticipating results.
The outcome of this study could significantly impact Dbv Technologies’ stock performance, as successful results may enhance their market position in pediatric allergy treatments. Investors should monitor this study closely, considering the competitive landscape in allergy therapeutics.
The study is ongoing, with further details available on the ClinicalTrials portal.